Bionik Laboratories Corp.
BNKL · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Revenue | $2 | $1 | $1 | $2 |
| % Growth | 41.7% | 6.7% | -44.6% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $1 |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 54.8% | 74.8% | 77.4% | 58.5% |
| R&D Expenses | $1 | $1 | $1 | $4 |
| G&A Expenses | $3 | $3 | $5 | $6 |
| SG&A Expenses | $5 | $5 | $6 | $8 |
| Sales & Mktg Exp. | $2 | $2 | $1 | $2 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6 | $6 | $7 | $12 |
| Operating Income | -$5 | -$5 | -$6 | -$11 |
| % Margin | -267.3% | -374.7% | -515.8% | -522.2% |
| Other Income/Exp. Net | -$0 | -$6 | -$7 | -$14 |
| Pre-Tax Income | -$5 | -$10 | -$14 | -$25 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$10 | -$14 | -$25 |
| % Margin | -274% | -817.1% | -1,141.3% | -1,157.9% |
| EPS | -0.72 | -1.78 | -2.66 | -5.6 |
| % Growth | 59.6% | 33.1% | 52.5% | – |
| EPS Diluted | -0.72 | -1.78 | -2.66 | -5.6 |
| Weighted Avg Shares Out | 7 | 6 | 5 | 4 |
| Weighted Avg Shares Out Dil | 7 | 6 | 5 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$9 | -$13 | -$24 |
| % Margin | -264.6% | -744.3% | -1,091.4% | -1,135.6% |